Brii Biosciences Limited (F:7SS) — Market Cap & Net Worth
Market Cap & Net Worth: Brii Biosciences Limited (7SS)
Brii Biosciences Limited (F:7SS) has a market capitalization of $87.69 Million (€75.00 Million) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #19790 globally and #1817 in its home market, demonstrating a -0.95% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Brii Biosciences Limited's stock price €0.10 by its total outstanding shares 721177062 (721.18 Million). Review 7SS liabilities breakdown to assess the company's total debt and financial obligations.
Brii Biosciences Limited Market Cap History: 2021 to 2026
Brii Biosciences Limited's market capitalization history from 2021 to 2026. Data shows change from $2.98 Billion to $87.69 Million (-45.81% CAGR).
Brii Biosciences Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Brii Biosciences Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.39x
Brii Biosciences Limited's market cap is 6.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $712.45 Million | $51.63 Million | -$484.31 Million | 13.80x | N/A |
| 2023 | $202.35 Million | $617.00K | -$174.83 Million | 327.96x | N/A |
| 2025 | $118.88 Million | $18.61 Million | -$222.62 Million | 6.39x | N/A |
Competitor Companies of 7SS by Market Capitalization
Companies near Brii Biosciences Limited in the global market cap rankings as of June 19, 2026.
Key companies related to Brii Biosciences Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Brii Biosciences Limited Historical Marketcap From 2021 to 2026
Between 2021 and today, Brii Biosciences Limited's market cap moved from $2.98 Billion to $ 87.69 Million, with a yearly change of -45.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €87.69 Million | -26.24% |
| 2025 | €118.88 Million | +18.49% |
| 2024 | €100.33 Million | -50.42% |
| 2023 | €202.35 Million | -71.60% |
| 2022 | €712.45 Million | -76.13% |
| 2021 | €2.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Brii Biosciences Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $87.69 Million USD |
| MoneyControl | $87.69 Million USD |
| MarketWatch | $87.69 Million USD |
| marketcap.company | $87.69 Million USD |
| Reuters | $87.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Brii Biosciences Limited
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neut… Read more